Skip to main content

news

 

Indian law firm Cyril Amarchand Mangaldas has advised global PE investor Advent International on its 24.75-billion-rupee (nearly $297 million) investment in Apollo Hospitals’ (AHE) unit Apollo HealthCo.

Apollo HealthCo was represented by Shardul Amarchand Mangaldas & Co, while AZB & Partners counselled AHE.

Following the deal, Apollo HealthCo will merge its online pharmacy business, Apollo 24/7, with pharmacy distributor Keimed.

Apollo HealthCo will have an enterprise value of 144.78 billion rupees, while Keimed is valued at 80.03 billion rupees, Reuters reported, adding that the merged entity is expected to deliver revenue worth 250 billion rupees in the next three years.

The SAM transaction team, which advised Apollo HealthCo, was led by partners Puja Sondhi and Aayush Kapoor, who were assisted by principal associate Roma Das and associates Prerna Saroha and Harjas Singh.

Partners Ashni Roy, Manita Doshi, Harman Singh Sandhu and Rohan Arora also assisted on ancillary aspects of the deal.

The AZB team that advised AHE was led by senior partner Aarthi Sivanandh and partner Bhavana Alexander.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

CAM, Trilegal, Khaitan, IndusLaw act on HUL’s $350 mln Minimalist deal

by Nimitt Dixit |

In the first big M&A deal in India this year, leading firm Cyril Amarchand Mangaldas has guided FMCG major Hindustan Unilever (HUL) on its acquisition of 90.5 percent stake in Jaipur-based skincare startup Minimalist for close to $350 million (29.5 billion rupees).

Deals

7 international, Indian firms act on Kedaara Capital’s $350 mln U.S. bet

by Nimitt Dixit |

Akin Gump Strauss Hauer & Feld, Quillon Partners, and Kelley Drye & Warren have advised Indian private equity firm Kedaara Capital on its maiden bet in the data analytics and AI solutions market, committing $350 million strategic investment to San Jose, California-based Impetus Technologies.

Deals

Saraf, TT&A facilitate Fortis’ $207 mln buyout of PE investors in Agilus Diagnostics

by Nimitt Dixit |

Saraf and Partners has acted for Fortis Healthcare in relation to the $207 million acquisition of a 31.5 percent equity stake in its subsidiary, Agilus Diagnostics, from three private equity investors.